Skip to main content

Advertisement

SpringerLink
Log in

Cerebellar ataxia

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

  • There is nothing more discouraging than for a patient to be given a specific diagnosis, then to be told that there is nothing that can be done. Physicians are equally disheartened to see exponential progress being made in the understanding of the pathophysiology of a complex disorder but few direct benefits resulting for their patients. Over the past 5 years, molecular genetic research has completely revolutionized the way in which the progressive cerebellar ataxias are classified and diagnosed, Class IIa], but it has yet to produce effective gene-based, neuroprotective, or neurorestorative therapies.

  • The treatment of cerebellar ataxia remains primarily a neurorehabilitation challenge, employing physical, occupational, speech, and swallowing therapy; adaptive equipment; driver safety training; and nutritional counseling. Modest additional gains are seen with the use of medications that can improve imbalance, incoordination, or dysarthria (amantadine, buspirone, acetazolamide); cerebellar tremor (clonazepam, propranolol); and cerebellar or central vestibular nystagmus (gabapentin, baclofen, clonazepam). Many of the progressive cerebellar syndromes have associated features involving other neurologic systems (eg, spasticity, dystonia or rigidity, resting or rubral tremor, chorea, motor unit weakness or fatigue, autonomic dysfunction, peripheral or posterior column sensory loss, neuropathic pain or cramping, double vision, vision and hearing loss, dementia, and bowel, bladder, and sexual dysfunction), which can impede the treatment of the ataxic symptoms or can worsen with the use of certain drugs. Treatment of the associated features themselves may in turn worsen the ataxia either directly (as side effects of medication) or indirectly (eg, relaxation of lower limb spasticity that was acting as a stabilizer for an ataxic gait). Secondary complications of progressive ataxia can include deconditioning or immobility, weight loss or gain, skin breakdown, recurrent pulmonary and urinary tract infections, aspiration, occult respiratory failure, and obstructive sleep apnea, all of which can be life threatening. Depression in the patient and family members is common.

  • Although no cures exist for most of the causes of cerebellar ataxia and there are as yet no proven ways to protect neurons from premature cell death or to restore neuronal populations that have been lost, symptomatic treatment can greatly improve the quality of life of these patients and prevent complications that could hasten death. Supportive interventions should always be offered—education about the disease itself, genetic counseling, individual and family counseling, referral to support groups and advocacy groups, and guidance to online resources. Misinformation, fear, depression, hopelessness, isolation, and financial and interpersonal stress can often cause more harm to the patient and caregiver than the ataxia itself.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mosely ML, Benzow KA, Schut LJ, et al.: Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 1998, 51:1666–1671. This report demonstrates the power of the new molecular genetic diagnostic techniques and lays the groundwork for future gene-based therapies.

    Google Scholar 

  2. Oertel WH: Neurotransmitters in the cerebellum. Scientific aspects and clinical relevance. In Inherited Ataxias. Edited by Harding AE, Deufel T. New York: Raven Press; 1993:33–75. This is a comprehensive review of the basic science behind the development of drug treatment for ataxia.

    Google Scholar 

  3. Wexler ID, Hemalatha SG, McConnell J, et al.: Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology 1997, 49:1655–1661.

    PubMed  CAS  Google Scholar 

  4. Steinberg D: Elucidation of the metabolic error in Refsum’s disease. Strategy and tactics. In The Inherited Ataxias. Edited by Kark RAP, Rosenberg RN, Schut LJ. New York: Raven Press; 1978:113–124.

    Google Scholar 

  5. Moser HW, Borel J: Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr 1995, 15:379–397.

    Article  PubMed  CAS  Google Scholar 

  6. Peynet J, Laurent A, De Liege P, et al.: Cerebrotendinous xanthomatosis. Treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings. Neurology 1991, 41:434–436.

    PubMed  CAS  Google Scholar 

  7. MacGilchrist AJ, Mills PR, Noble M, et al.: Abetalipoproteinaemia in adults. Role of vitamin therapy. J Inherit Metab Dis 1988, 11:184–190.

    Article  PubMed  CAS  Google Scholar 

  8. Battisti C, Toffola ED, Verri AP, et al.: Clinical and stabilometric monitoring in a case of cerebellar atrophy with vitamin E deficiency. Brain Dev 1998, 20:253–257.

    Article  PubMed  CAS  Google Scholar 

  9. Dropcho EJ: Autoimmune central nervous system paraneoplastic disorders. Mechanisms, diagnosis, and therapeutic options. Ann Neurol 1995, 37(suppl 1):S102-S113. A thorough review of this important area of cancer management is presented.

    Article  PubMed  Google Scholar 

  10. Notermans NC, van Dijk GW, van der Graaf Y, et al.: Measuring ataxia. Quantification based on the standard neurological examination. J Neurol Neurosurg Psychiatry 1994, 57:22–26. This is a useful aid in the assessment of treatment effectiveness.

    PubMed  CAS  Google Scholar 

  11. D’Ambrosio R, Leone M, Rosso MG, et al.: Disability and quality of life in hereditary ataxias. A self-administered postal questionnaire. Int Disabil Stud 1987, 9:10–14. This is another useful aid in the assessment of treatment effectiveness.

    PubMed  CAS  Google Scholar 

  12. White R, Frank E: Health effects and prevalence of vegetarianism. West J Med 1994, 160:465–471.

    PubMed  CAS  Google Scholar 

  13. Peterson PL, Saad J, Nigro MA: The treatment of Friedreich’s ataxia with amantadine hydrochloride. Neurology 1988, 38:1478–1480.

    PubMed  CAS  Google Scholar 

  14. Filla A, De Michele G, Orefice G, et al.: A double-blind cross-over trial of amantadine hydrochloride in Friedreich’s ataxia. Can J Neurol Sci 1993, 20:52–55.

    PubMed  CAS  Google Scholar 

  15. Botez MI, Botez-Marquard T, Elie R, et al.: Amantadine hydrochloride treatment in heredodegenerative ataxias. A double blind study. J Neurol Neurosurg Psychiatry 1996, 61:259–264.

    PubMed  CAS  Google Scholar 

  16. Trouillas P, Brudon F, Adeleine P: Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol 1988, 45:1217–1222.

    PubMed  CAS  Google Scholar 

  17. Trouillas P, Serratrice G, Laplane D, et al.: Levorotatory form of 5-hydroxytryptophan in Friedreich’s ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol 1995, 52:456–460.

    PubMed  CAS  Google Scholar 

  18. Wessel K, Hermsdorfer J, Deger K, et al.: Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases. Arch Neurol 1995, 52:451–455.

    PubMed  CAS  Google Scholar 

  19. Currier RD, Collins GM, Subramony SH: Treatment of hereditary ataxia with the levorotatory form of hydroxytryptophan. Arch Neurol 1995, 52:440–441.

    PubMed  CAS  Google Scholar 

  20. Manto M, Hildebrand J, Godaux E, et al.: Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy. Failure of L-hydroxytryptophan to improve cerebellar ataxia. Arch Neurol 1997, 54:1192–1194.

    PubMed  CAS  Google Scholar 

  21. Friedman JH: Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord 1997, 12:613–614.

    Article  PubMed  CAS  Google Scholar 

  22. Lou JS, Goldfarb L, McShane L, et al.: Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol 1995, 52:982–988.

    PubMed  CAS  Google Scholar 

  23. Trouillas P, Xie J, Adeleine P, et al.: Buspirone, a 5-hydroxytryptamine 1A agonist, is active in cerebellar ataxia. Results of a double-blind drug-placebo study in patients with cerebellar cortical atrophy. Arch Neurol 1997, 54:749–752. This is a well-designed study of 19 patients with cerebellar cortical atrophy that establishes buspirone as a useful adjunctive agent for the treatment of ataxia.

    PubMed  CAS  Google Scholar 

  24. Cappelli A, Anzini M, Vomero S, et al.: Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors. J Med Chem 1999, 42:1556–1575.

    Article  PubMed  CAS  Google Scholar 

  25. Rice GP, Lesaux J, Vandervoort P, et al.: Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997, 62:282–284.

    PubMed  CAS  Google Scholar 

  26. Kark RAP, Budelli MMR, Wachsner R: Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias. Neurology 1981, 31:288–292.

    PubMed  CAS  Google Scholar 

  27. Aschoff JC, Kailer NA, Walter K: Physostigmine in treatment of cerebellar ataxia. Nervenarzt 1996, 67:311–318.

    PubMed  CAS  Google Scholar 

  28. Manyam BV, Giacobini E, Ferraro TN, et al.: Cerebrospinal fluid as a reflector of central cholinergic and amino acid neurotransmitter activity in cerebellar ataxia. Arch Neurol 1990, 47:1194–1199.

    PubMed  CAS  Google Scholar 

  29. Wessel K, Langenberger K, Nitschke MF, et al.: Doubleblind crossover study with physostigmine in patients with degenerative cerebellar diseases. Arch Neurol 1997, 54:397–400.

    PubMed  CAS  Google Scholar 

  30. Lambert D, Waters CH: Essential tremor. Curr Treat Options Neurol 1999, 1:6–13. This is a superb review of kinetic tremor as it applies to cerebellar disease.

    Article  PubMed  Google Scholar 

  31. Bonuccelli U, Nuti A, Cei G, et al.: Oral thyrotropinreleasing hormone treatment in inherited ataxias. Clin Neuropharmacol 1988, 11:520–528.

    Article  PubMed  CAS  Google Scholar 

  32. Filla A, De Michele G, Di Martino L, et al.: Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects [in Italian]. Riv Neurol 1989, 59:83–88.

    PubMed  CAS  Google Scholar 

  33. Waragai M, Ogawara K, Takaya Y, et al.: Efficacy of TRH-T for spinocerebellar degeneration. The relation between clinical features and effect of TRH therapy [in Japanese]. Rinsho Shinkeigaku 1997, 37:587–594.

    PubMed  CAS  Google Scholar 

  34. Manyam BV: Recent advances in the treatment of cerebellar ataxia. Clin Neuropharmacol 1986, 9:508–516.

    Article  PubMed  CAS  Google Scholar 

  35. Blumberg EA, Gil RA: Cerebellar syndrome caused by isoniazid. DICP 1990, 24:829–831.

    PubMed  CAS  Google Scholar 

  36. Shu YD, Chang MK, Hsein HH: Isoniazid therapy in severe cerebellar, postural, and kinetic tremor [in Chinese]. Chung Hua I Hsueh Tsa Chih 1989, 43:292–298.

    PubMed  CAS  Google Scholar 

  37. Sechi GP, Zuddas M, Piredda M, et al.: Treatment of cerebellar tremors with carbamazepine. A controlled trial with long-term follow-up. Neurology 1989, 39:1113–1115.

    PubMed  CAS  Google Scholar 

  38. Averbuch-Heller L: Acquired nystagmus. Curr Treat Options Neurol 1999, 1:68–73. This is a superb review of nystagmus as it applies to cerebellar disease.

    Article  PubMed  Google Scholar 

  39. Jen JC, Yue Q, Karrim J, et al.: Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia. J Neurol Neurosurg Psychiatry 1998, 65:565–568. The area of overlapping phenotypes in the ataxic ion channelopathies is clarified.

    PubMed  CAS  Google Scholar 

  40. Lubbers WJ, Brunt ER, Scheffer H, et al.: Hereditary myokymia and paroxysmal ataxia linked to chromosome 12 is responsive to acetazolamide. J Neurol Neurosurg Psychiatry 1995, 59:400–405.

    PubMed  CAS  Google Scholar 

  41. Baig SM: Acetazolamide therapy improves action myoclonus in Ramsay Hunt syndrome. J Neurol Sci 1997, 145:123–124.

    Article  PubMed  CAS  Google Scholar 

  42. Olesen J: Calcium entry blockers in the treatment of vertigo. Ann N Y Acad Sci 1988, 522:690–697.

    Article  PubMed  CAS  Google Scholar 

  43. Boel M, Casaer P: Familial periodic ataxia responsive to flunarizine. Neuropediatrics 1988, 19:218–220.

    PubMed  CAS  Google Scholar 

  44. Seliger GM, Hornstein A: Serotonin, fluoxetine, and pseudobulbar affect. Neurology 1989, 39:1400. The first really effective drug option for brain stem-mediated dysarthria and dysphagia is presented.

    PubMed  CAS  Google Scholar 

  45. Finsterer J, Muellbacher W, Mamoli B: Yes/yes head tremor without appendicular tremor after bilateral cerebellar infarction. J Neurol Sci 1996, 139:242–245.

    Article  PubMed  CAS  Google Scholar 

  46. Pullman SL, Greene P, Fahn S, et al.: Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996, 53:617–624.

    PubMed  CAS  Google Scholar 

  47. Nguyen JP, Feve A, Keravel Y: Is electrostimulation preferable to surgery for upper limb ataxia? Curr Opin Neurol 1996, 6:445–450.

    Article  Google Scholar 

  48. Koch SJ, Arego DE, Bowser B: Outpatient rehabilitation for chronic neuromuscular diseases. Am J Phys Med 1986, 65:245–257.

    PubMed  CAS  Google Scholar 

  49. Perlman SL, Kern RI: Intensive physical therapy for chronic progressive neuromuscular disease [abstract]. Musc Nerv 1986, 9:257. A prospective nonrandomized study of 20 patients with a variety of cerebellar syndromes is discussed, demonstrating qualitative and quantitative gains in function.

    Article  Google Scholar 

  50. Bastian AJ: Mechanisms of ataxia. Phys Ther 1997, 77:672–675.

    PubMed  CAS  Google Scholar 

  51. Jobst U: Posturographic biofeedback training in equilibrium disorders [in German]. Fortschr Neurol Psychiatr 1989, 57:74–80.

    Article  PubMed  CAS  Google Scholar 

  52. Strupp M, Arbusow V, Maag KP, et al.: Vestibular exercises improve central vestibulospinal compensation after vestibular neuritis. Neurology 1998, 51:838–844.

    PubMed  CAS  Google Scholar 

  53. Rosenberg RN: Alternative neurology. Arch Neurol 1998, 55:1394–1395.

    Article  PubMed  CAS  Google Scholar 

  54. Zwicky JF, Hafner AW, Barrett S, et al. Reader’s Guide to Alternative Health Methods. Washington, DC: American Medical Association; 1993. This is a critical analysis of more than 1000 reports on unproven, disproven, controversial, fraudulent, quack, or otherwise questionable approaches to solving health problems. The baby may be thrown out with the bath water, however; the book does not recognize the renewed hope that these patient-empowering approaches may engender.

    Google Scholar 

  55. Waldvogel D, van Gelderen P, Hallett M: Increased iron in the dentate nucleus of patients with Friedreich’s ataxia. Ann Neurol 1999, 46:123–125.

    Article  PubMed  CAS  Google Scholar 

  56. Schapira AH: Mitochondrial dysfunction in neurodegenerative disorders. Biochim Biophys Acta 1998, 1366:225–233. A clear and thorough review of current thinking regarding the pathogenesis of neurodegeneration and possible treatment strategies is presented.

    Article  PubMed  CAS  Google Scholar 

  57. Hurd RW, Wilder BJ, Helveston WR, et al.: Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996, 47:1264–1268.

    PubMed  CAS  Google Scholar 

  58. Fernandez AM, de la Vega AG, Torres-Aleman I: Insulinlike growth factor I restores motor coordination in a rat model of cerebellar ataxia. Proc Natl Acad Sci U S A 1998, 95:1253–1258.

    Article  PubMed  CAS  Google Scholar 

  59. Cheng-yuan W, Xiu-feng B, Cheng Z, et al.: Fetal tissue grafts for cerebellar atrophy. Chin Med J 1991, 104:198–203.

    Google Scholar 

  60. National Ataxia Foundation Web site: http:// www.ataxia.org. This is a well-developed, informative resource for clinician and patient alike, highlighting advances in diagnosis and treatment of ataxic disorders.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of California at Los Angeles, 300 UCLA Medical Plaza, Suite B200, 90095, Los Angeles, CA, USA

    Susan L. Perlman MD

Authors
  1. Susan L. Perlman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perlman, S.L. Cerebellar ataxia. Curr Treat Options Neurol 2, 215–224 (2000). https://doi.org/10.1007/s11940-000-0004-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-000-0004-3

Keywords

Search

Navigation